Cargando…

Measurement of PD-L1 in melanoma: a quantitative antibody comparison

Detalles Bibliográficos
Autores principales:	Sunshine, Joel C, Berry, Sneha, Esandrio, Jessica, Xu, Haiying, Ogurtsova, Aleksandra, Cornish, Toby, Lipson, Evan J, Anders, Robert A, Taube, Janis M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645465/ http://dx.doi.org/10.1186/2051-1426-3-S2-P107

Ejemplares similares

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
por: Giraldo, Nicolas A., et al.
Publicado: (2018)

PD-L1 Expression in Inflammatory Myofibroblastic Tumors
por: Cottrell, Tricia R., et al.
Publicado: (2018)

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
por: Postow, Michael A, et al.
Publicado: (2014)

Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies
por: Lipson, Evan J.
Publicado: (2013)

PD-L1 expression in medulloblastoma: an evaluation by subgroup
por: Martin, Allison M., et al.
Publicado: (2018)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

Immune cell subsets in interface cutaneous immune‐related adverse events associated with anti‐PD‐1 therapy resemble acute graft versus host disease more than lichen planus
por: Almodovar Cruz, Guillermo E., et al.
Publicado: (2022)

Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures
por: Cheung, Laurene S, et al.
Publicado: (2021)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting
por: Lipson, Evan J, et al.
Publicado: (2015)

Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients
por: Dronca, Roxana, et al.
Publicado: (2015)

Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?
por: Bender, Carolin, et al.
Publicado: (2017)

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma
por: Deutsch, Julie Stein, et al.
Publicado: (2023)

High frequency CD8+PD-1+ TCR clonotypes isolated from fresh melanomas display anti-tumor activity
por: Anna, Pasetto, et al.
Publicado: (2015)

Data analysis of PD-1 antibody in the treatment of melanoma patients
por: Li, Ting, et al.
Publicado: (2020)

Antibody response to melanoma helper-peptide vaccine correlates with survival
por: Olson, Walter C, et al.
Publicado: (2013)

Developing a quantitative model of antibody effector function
por: Boesch, AW, et al.
Publicado: (2012)

Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
por: Sahni, Sakshi, et al.
Publicado: (2018)

Selinexor, a selective inhibitor of nuclear export (SINE), shows enhanced activity in combination with PD-1/PD-L1 blockade in syngeneic murine models of colon cancer and melanoma
por: Farren, Matthew R, et al.
Publicado: (2015)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Targeting of phosphatidylserine by monoclonal antibodies augments the activity of paclitaxel and anti-PD1/PD-L1 therapy in the murine breast model E0771
por: Gray, Michael, et al.
Publicado: (2015)

Virus-specific CD8+ T cells infiltrate melanoma lesions and retain function despite high PD-1 expression
por: Erkes, Dan A, et al.
Publicado: (2015)

Quantitative Dynamic (18)F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Functional properties of patient-derived melanoma cancer stem cells
por: Nistor, Gabriel, et al.
Publicado: (2015)

Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma
por: Morales-Betanzos, Carlos A., et al.
Publicado: (2017)

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
por: Callahan, Margaret K, et al.
Publicado: (2013)

PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis
por: Lin, Zhijuan, et al.
Publicado: (2016)

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma
por: Sharma, Gaurav, et al.
Publicado: (2020)

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma
por: Sharma, Gaurav, et al.
Publicado: (2022)

Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in Solid Tumors
por: Gong, Chang, et al.
Publicado: (2019)

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
por: Wong, Michael KK, et al.
Publicado: (2015)

Clinical scale zinc finger nuclease (ZFN)-driven gene-editing of PD-1 in tumor infiltrating lymphocytes (TIL) for the potential treatment of metastatic melanoma
por: Beane, Joal D, et al.
Publicado: (2014)

A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain
por: Ruzevick, Jacob, et al.
Publicado: (2013)

A Case Report of Primary Recurrent Malignant Melanoma of the Urinary Bladder
por: Truong, Hong, et al.
Publicado: (2013)

Expression of programmed death (PD)-1 and PD-1 ligands (PD-L1, PD-L2) in peripheral blood mononuclear cells of patients with systemic lupus erythematosus
por: Bertsias, G, et al.
Publicado: (2005)

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
por: Vavolizza, Rick D, et al.
Publicado: (2022)

Anti-tumor antibody profile analysis to harness the potentials of B cells in melanomas and the natural humoral immune response
por: Kotlan, Beatrix, et al.
Publicado: (2013)

Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer
por: Mace, Thomas, et al.
Publicado: (2015)

Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody
por: Lee, Jiyun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ov6eo31nc679usphrtesv11ti9